Fusion Antibodies plc (AIM:FAB)

London flag London · Delayed Price · Currency is GBP · Price in GBX
13.50
-0.25 (-1.82%)
Oct 10, 2025, 4:29 PM GMT+1
-1.82%
Market Cap15.34M
Revenue (ttm)1.97M
Net Income (ttm)-1.71M
Shares Out113.66M
EPS (ttm)-0.02
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume3,011,676
Average Volume1,515,973
Open13.99
Previous Close13.75
Day's Range12.50 - 15.00
52-Week Range3.81 - 21.00
Beta0.87
RSI37.43
Earnings DateNov 19, 2025

About Fusion Antibodies

Fusion Antibodies plc, a contract research organization, engages in the research, development, and manufacture of recombinant proteins and antibodies for cancer and infectious diseases in the United Kingdom, the rest of Europe, North America, and internationally. The company offers monoclonal antibody discovery and development, antibody sequencing, antibody engineering, antibody humanization and rational affinity maturation platform, recombinant protein expression, and stable cell line development and cGMP scale up services. It serves pharmaceu... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2000
Employees 24
Stock Exchange London Stock Exchange AIM
Ticker Symbol FAB
Full Company Profile

Financial Performance

In 2024, Fusion Antibodies's revenue was 1.97 million, an increase of 72.98% compared to the previous year's 1.14 million. Losses were -1.71 million, -23.05% less than in 2023.

Financial Statements

News

There is no news available yet.